How many insider trades does FilingIQ track for GOSS?

FilingIQ tracks 234 Form 4 insider transactions for GOSS (Gossamer Bio, Inc.), covering filings from Feb 12, 2019 onwards. 114 of those were filed in the last 90 days.

Are GOSS insiders net buyers or net sellers?

Across the full Form 4 history for GOSS, 28 transactions (12%) were open-market purchases and 41 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GOSS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GOSS in?

Gossamer Bio, Inc. (GOSS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $97.77M.

GOSS insider trading

NasdaqGS Healthcare

Gossamer Bio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

234

Last 90 days

114

Buys / sells

12% / 18%

Market cap

$97.77M

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Company website: www.gossamerbio.com

GOSS insider activity at a glance

FilingIQ has scored 234 insider transactions for GOSS since Feb 12, 2019. The most recent filing in our index is dated Mar 19, 2026.

Across the full history, 28 open-market purchases and 41 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GOSS insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GOSS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding GOSS

VR Adviser, LLC

$20.93M · 3.2% of AUM

Opaleye Management Inc.

$8.43M · 1.1% of AUM

Frequently asked

How many insider trades does FilingIQ track for GOSS?: FilingIQ tracks 234 Form 4 insider transactions for GOSS (Gossamer Bio, Inc.), covering filings from Feb 12, 2019 onwards. 114 of those were filed in the last 90 days.
Are GOSS insiders net buyers or net sellers?: Across the full Form 4 history for GOSS, 28 transactions (12%) were open-market purchases and 41 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GOSS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GOSS in?: Gossamer Bio, Inc. (GOSS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $97.77M.

Methodology & sources

Every GOSS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.